BofA warns Fed risks policy mistake with early rate cuts
Karen Prange, a director at AtriCure , Inc. (NASDAQ:ATRC), a $1.77 billion market cap company with a "GOOD" InvestingPro Financial Health score, recently sold 6,100 shares of the company’s common stock. The shares were sold at a weighted average price of $38.12, resulting in a total transaction value of $232,531. This transaction was executed on March 5, 2025, with prices ranging from $37.60 to $38.52 per share. Following the sale, Prange holds 17,828 shares of AtriCure. The stock has shown significant momentum with a 38% gain over the past six months, though InvestingPro analysis indicates high price volatility. Get access to 7 more exclusive ProTips and comprehensive analysis in the Pro Research Report.
In other recent news, AtriCure Inc. reported its Q4 2024 earnings, revealing a notable revenue increase of 16.6% year-over-year, reaching $124.3 million. Despite this revenue growth, the company reported a wider-than-expected loss per share of -$0.33, missing the forecasted -$0.20. Analysts from BTIG raised the company’s stock price target to $57 while maintaining a Buy rating, citing the strong revenue performance, particularly in the U.S. cryoSPHERE pain management and international markets. JMP Securities also reaffirmed a Market Outperform rating with a $60 target, expressing confidence in AtriCure’s growth potential, driven by its diverse portfolio and upcoming initiatives for 2025 and 2026. Needham maintained a Buy rating with a $51 target, highlighting that AtriCure’s EBITDA and earnings per share surpassed market expectations. The company has set its 2025 revenue guidance between $517 million and $527 million, projecting an 11-13% year-over-year increase. AtriCure’s adjusted EBITDA expectations for 2025 have been revised to $42 million to $44 million, reflecting anticipated operational leverage improvements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.